MDL 2738: Xarelto Litigation & 2024 Settlement Status Guide

Table of Contents#

1. What Is MDL 2592?
2. Background of Xarelto Litigation
3. Key Milestones in the Xarelto MDL (MDL 2592)
4. Xarelto Settlement Status and Recent Updates
5. Eligibility Criteria for Xarelto Settlement Compensation
6. Types of Damages Covered in Xarelto Settlements
7. Next Steps If You Believe You Have a Xarelto Claim
8. Frequently Asked Questions (FAQs)
9. References

---

What Is MDL 2592?#

The H1 title of this guide references MDL 2738, which is the formal designation for the In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation docket in New Jersey. However, for patients filing lawsuits over Xarelto injuries, the correct federal docket is MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation).

MDL 2592 was hosted in the U.S. District Court for the Eastern District of Louisiana and overseen by Judge Eldon E. Fallon. Multidistrict litigations (MDLs) are a legal tool used to group thousands of similar civil cases in one court to avoid duplicate pre-trial proceedings, reduce costs for plaintiffs and the court system, and speed up resolution. All cases in MDL 2592 shared the same core allegation: that manufacturers Bayer and Janssen Pharmaceuticals misrepresented Xarelto’s safety profile and failed to warn patients and healthcare providers of its severe, potentially fatal bleeding risks.

Background of Xarelto Litigation#

Xarelto was first approved by the U.S. FDA in 2011 as a factor Xa inhibitor blood thinner, marketed as a more convenient alternative to the older blood thinner warfarin. Unlike warfarin, Xarelto did not require regular blood level monitoring, making it a popular option for patients at risk of blood clots, including those with atrial fibrillation, post-surgery patients, and people with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE).

The core controversy stems from the fact that no FDA-approved reversal agent for Xarelto existed until 2018. This meant that patients who experienced a bleeding event while taking Xarelto had no way to stop the bleeding quickly, leading to avoidable hospitalizations, permanent brain damage, and death. Plaintiffs alleged that the manufacturers knew about this risk as early as clinical trials but hid data from regulators and the public to protect Xarelto’s multi-billion dollar sales.

The Reversal Agent and Recent Changes#

In 2018, the FDA granted accelerated approval to Andexxa (andexanet alfa) as a specific reversal agent for Factor Xa inhibitors like Xarelto. However, the safety landscape shifted:

• Andexxa Voluntary Withdrawal (Late 2025): Effective December 22, 2025, AstraZeneca voluntarily withdrew Andexxa from the U.S. market. The withdrawal was prompted by post-marketing safety data showing an increased risk of serious and fatal thromboembolic events (blood clots) in patients treated with Andexxa, which outweighed its clinical benefits.
• Current Standard of Care: Following the withdrawal, healthcare providers have transitioned to alternative strategies, primarily off-label 4-factor Prothrombin Complex Concentrate (4F-PCC), to manage emergent, life-threatening bleeding in patients taking Xarelto.

Key Milestones in the Xarelto MDL (MDL 2592)#

The MDL progressed through several key stages since its centralization:

1. December 2014: MDL 2592 was established by the Judicial Panel on Multidistrict Litigation (JPML).
2. 2015–2018: Bellwether trials (test cases used to gauge jury sentiment for settlement negotiations) were held in both federal and state courts. In December 2017, a Philadelphia jury awarded a $27.8 million verdict to a plaintiff who suffered internal bleeding, though this verdict was subsequently overturned by a judge in January 2018 on a narrow prescribing physician issue.
3. March 2019: A major global settlement was announced, with Bayer and Janssen Pharmaceuticals agreeing to pay $775 million to resolve approximately 25,000 eligible claims. Average payouts under this settlement were structured based on injury severity, and the claims process concluded by 2021.
4. 2022–2026: Filing activity in MDL 2592 ceased. The MDL was systematically wound down, and by 2026, the Judicial Panel on Multidistrict Litigation reports showed zero pending actions in MDL 2592, reflecting the resolution or dismissal of the remaining cases.

Xarelto Settlement Status and Recent Updates#

For patients and families looking for current settlement options, the legal landscape depends on geographic location:

1. United States Status#

• MDL Resolution: The U.S. federal multidistrict litigation (MDL 2592) has officially concluded. The $775 million settlement from 2019 resolved the vast majority of personal injury claims in the country.
• Current Filings: There are no new global or multidistrict personal injury settlements for Xarelto. Claims filed outside the original settlement window are subject to strict state-level statutes of limitations (typically 2 to 3 years from the date the injury was discovered).
• Patent Disputes: Recent litigation in the U.S. and Europe has shifted toward patent disputes, where generic drug manufacturers have challenged Bayer's patents to allow generic versions of rivaroxaban to enter the market.

2. Canada Class Action Settlement (2025–2026)#

• The Proposed Settlement: A Canada-wide class action settlement was reached in late 2025, providing a compensation fund of $4.5 million to$5.25 million for eligible Canadian residents who ingested Xarelto and suffered qualifying bleeding injuries.
• Deadlines: The deadline to opt out of the Canadian class action was March 10, 2026. Court approval hearings were held in the spring of 2026, and the claims administrator (MNP) is managing the claim intake process via the official website, www.mnp.ca/xareltosettlement.

Eligibility Criteria for Xarelto Settlement Compensation#

Because the original U.S. MDL 2592 global settlement claims window is closed, current eligibility is limited. However, to understand how the historical U.S. settlement payouts were determined, the criteria included:

1. Prescription History: The claimant was prescribed brand-name Xarelto (generic rivaroxaban was not approved in the U.S. until late 2021).
2. Severe Injury: The patient experienced a severe bleeding event (such as a gastrointestinal bleed, brain bleed, hemorrhagic stroke, or other uncontrolled bleeding) that required hospitalization, or a bleeding event resulted in death.
3. No Prior Recovery: The claimant did not already receive a payout from the 2019 settlement.
4. Statute of Limitations: For individual claims filed outside the MDL, the action must comply with state-specific deadlines.

For Canadian residents, the 2025–2026 class action settlement requires:

1. Ingestion of brand-name Xarelto in Canada prior to October 27, 2025.
2. Occurrence of a qualifying bleeding injury.
3. Submission of necessary medical and prescription documentation before the court-established claims deadline.

Types of Damages Covered in Xarelto Settlements#

In resolved product liability settlements, eligible claimants recovered compensation for two categories of damages:

1. Economic Damages#

• Past and future medical bills related to the bleeding event.
• Lost wages and lost future earning capacity if the injury prevented the claimant from working.
• Funeral and burial costs in wrongful death claims.
• Costs associated with long-term care for permanent injuries (e.g., permanent brain damage from a stroke).

2. Non-Economic Damages#

• Physical pain and suffering.
• Loss of quality of life and enjoyment of activities.
• Severe emotional distress.
• Loss of consortium for spouses of injured or deceased claimants.

Next Steps If You Believe You Have a Xarelto Claim#

If you or a loved one suffered a bleeding event while taking Xarelto:

1. Consult a Medical Professional: Prioritize health and discuss safe anticoagulation alternatives. Do not discontinue taking Xarelto without consulting your doctor, as sudden discontinuation increases the risk of stroke.
2. Gather Documentation: Keep all records of Xarelto prescriptions, hospitalizations, medical bills, and doctor notes detailing the bleeding incident.
3. Consult a Qualified Attorney: Since the U.S. MDL has closed and deadlines have passed, a personal injury lawyer can evaluate whether you have a unique case that can be filed in state court or if you qualify under any other active regional proceedings (such as the Canadian settlement, if applicable).
4. Check Official Class Action Portals: Canadian claimants should visit www.mnp.ca/xareltosettlement to access forms and check submission deadlines.

Frequently Asked Questions (FAQs)#

Q: Is Xarelto still available on the market?#

A: Yes, Xarelto remains FDA-approved and is widely prescribed. It carries a boxed warning (the FDA’s strongest safety alert) highlighting the risks of blood clots if the medication is stopped prematurely, and the risks of spinal or epidural hematomas.

Q: Can I still file a claim in the U.S. MDL?#

A: No, the U.S. federal multidistrict litigation (MDL 2592) has closed with zero pending actions. The $775 million settlement announced in 2019 is complete, and the claims submission window has closed.

Q: What is the status of a generic version of Xarelto?#

A: While the FDA approved the first generic versions of rivaroxaban in late 2021, generic launch dates have been subject to ongoing patent litigation. In 2024 and 2025, court decisions in various jurisdictions have continued to impact the timing of generic entry.

Q: Who qualifies for the Canadian class action settlement?#

A: Canadian residents who took brand-name Xarelto prior to October 27, 2025, and experienced a qualifying bleeding injury. The opt-out deadline was March 10, 2026, and claims are administered through MNP.

---

References#

1. U.S. District Court for the Eastern District of Louisiana. (2019). In Re: Xarelto (Rivaroxaban) Products Liability Litigation (MDL No. 2592). Retrieved from https://www.laed.uscourts.gov
2. U.S. Judicial Panel on Multidistrict Litigation. (2026). MDL Statistics Report: Distribution of Pending MDL Dockets. Retrieved from https://www.jpml.uscourts.gov
3. U.S. Food and Drug Administration. (2025). Safety and Regulatory Status: Factor Xa Inhibitors and Reversal Agents. Retrieved from https://www.fda.gov
4. Siskinds LLP & Merchant Law Group. (2025). Canada-Wide Xarelto Class Action Settlement Agreement. Retrieved from https://www.mnp.ca/xareltosettlement
5. Philadelphia Court of Common Pleas. (2018). Hartman v. Janssen Pharmaceuticals, Inc., et al. (Order on Motion JNOV).